Unknown

Dataset Information

0

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.

ABSTRACT:

SUBMITTER: Duhrsen U 

PROVIDER: S-EPMC8129096 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.

Dührsen Ulrich U   Tometten Mareike M   Kroschinsky Frank F   Ganser Arnold A   Ibach Stefan S   Bertram Stefanie S   Hüttmann Andreas A  

Blood cancer journal 20210517 5

Similar Datasets

Unknown P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
| S-EPMC10431143 | biostudies-literature
Unknown Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
| S-EPMC3918114 | biostudies-literature
Unknown Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.
| S-EPMC8993776 | biostudies-literature
Unknown Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
| S-EPMC9122850 | biostudies-literature
Unknown Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC11609519 | biostudies-literature
Unknown A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC8253277 | biostudies-literature
Unknown Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
| S-EPMC5161005 | biostudies-literature
Unknown Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
| S-EPMC4283736 | biostudies-literature
Unknown Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
| S-EPMC9322457 | biostudies-literature
Unknown Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
| S-EPMC8711638 | biostudies-literature